Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news congress_bills wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi long-horizon policy question, so the market price is the primary anchor. Key drivers are whether Trump-era actions (Feb 2025 executive order, Oct 2025 TrumpRx/EMD Serono fertility drug deal, potential ACA essential-health-benefit designation, federal employee benefit mandates) go so far as to make at least one full IVF cycle free, plus any legislation. Research should establish current price, the status of announced IVF policy actions, and any congressional vehicles.

# Current state As of late July 2026, no federal action has eliminated the cost of an IVF cycle. Trump's Feb 2025 EO directed policy recommendations but created no mandate; subsequent actions (TrumpRx/EMD Serono drug discounts, FEHB state-law alignment, proposed excepted-benefits rule) reduce costs at the margins only. Kalshi YES sits at 15%, reflecting market skepticism that a true "free cycle" threshold will be met by close. # Timeline of key events - 2025-02-18 (confirmed): Trump signs EO directing HHS/DPC to recommend ways to expand IVF access and reduce costs within 90 days; explicitly non-binding, no mandate. [whitehouse.gov] - 2025-08 (reported): WaPo reports White House will not pursue a coverage mandate; would require Congress, admin doesn't plan to push legislation. [Rolling Stone] - 2025-10-16 (confirmed): TrumpRx/EMD Serono deal announced — up to 84% discount on 3 IVF drugs (Gonal-F, Ovidrel, Cetrotide) starting Jan 2026; covers medications only, not full cycle cost (clinic/lab/physician fees). CNN explicitly notes this "falls far short" of the free-IVF promise. - 2025-11 (confirmed): FEHB 2026 plan year sees OPM mandate HMOs in IVF-mandate states match state coverage — most FEHB IVF-offering plans in history, but only 2 nationwide plans cover the full procedure; out-of-pocket costs remain substantial. - 2026-05-13 (confirmed): DOL/HHS/Treasury propose "Excepted Fertility Benefits" rule — voluntary standalone benefit category (like dental/vision) with $120,000 lifetime cap for private employers; does not mandate coverage, does not touch FEHB. - 2026-05-21 (reported): CNN assessment — "much more needs to be done"; ~30% of employers offer IVF benefits (down slightly from 2 years prior); cycle costs $25,000–$35,000. - 2026-06 (reported): GOP Senator's attempt to expand IVF access killed in NDAA negotiations (military IVF); Democrats (Murray, Schumer, Duckworth) attack broken promise, revive Right to IVF Act as midterm issue. - 2026-06-10 (reported): Trump admin moves to protect frozen embryos from destruction (separate embryo-policy action, not cost-related). - 2026-07-21 (reported): Catholic bishops ask Trump to change IVF insurance rule (pushback from pro-life side against even incremental coverage moves). # Event Will Trump take an action eliminating the cost of at least one IVF cycle before Jan 20, 2029? # Outcomes to forecast Yes / No # Kalshi market anchor **YES = 15%** (current). 30-day change +1%, 7-day flat. Range 13–17% over 65 days of data; avg daily volume only 31 contracts (thin market). No sharp move on Oct 2025 TrumpRx news or May 2026 rule proposal — market has treated incremental actions as insufficient to move probability meaningfully. # Sub-question answers 1. **Kalshi price/history** — 15% YES, stable in 13–17% band for 65 days; low volume (~31 contracts/day); no major repricing despite multiple IVF news events, suggesting market already prices these as non-qualifying. [kalshi_direct] 2. **Concrete actions taken** — Feb 2025 EO (non-binding), Oct 2025 TrumpRx/EMD Serono drug discount (up to 84% off 3 drugs, meds only), 2026 FEHB state-law alignment, May 2026 proposed voluntary excepted-benefits rule ($120K cap). None eliminate full cycle cost; CNN/multiple outlets explicitly say these fall short of "free IVF." [CNN, claude_news] 3. **Pending mandate plans** — None. Aug 2025 WaPo reporting confirms White House explicitly declined to pursue mandate; May 2026 rule is voluntary/employer-only, doesn't touch FEHB or Medicaid/Medicare. No essential-health-benefit or Medicaid IVF designation reported. [Rolling Stone, claude_news] 4. **Congressional legislation** — Multiple Democratic bills (Protect IVF Act, Access to Fertility Treatment and Care Act, IVF for Military Families Act, Equal Access to Reproductive Care Act) all stalled in committee; a GOP NDAA amendment for military IVF was killed in negotiations (June 2026). No bill has GOP majority support or floor momentum. [congress_bills, gdelt_news] 5. **IVF cycle cost / resolution bar** — Full cycle costs $25,000–$35,000 (CNN, May 2026); current relief only covers a subset of drug costs (~$5-6K portion), leaving the bulk of cycle cost (clinic, lab, monitoring, physician fees) unaddressed. True "free cycle" would require a much larger federal subsidy or mandate. 6. **Other markets** — Polymarket has no matching IVF market (0 results). No sportsbook coverage. Kalshi's own related-market scan found no additional IVF markets beyond this ticker; other Trump-promise markets (manufacturing 14.4%, spending cuts 2%) show similar broken-promise-market skepticism pattern. # Key facts (high-confidence, factual) 1. [whitehouse.gov] Feb 2025 EO is non-mandatory, policy-recommendation only. 2. [CNN, Oct 2025] TrumpRx deal cuts costs on 3 fertility drugs only, not full cycle. 3. [Rolling Stone, Aug 2025] Administration explicitly not pursuing coverage mandate. 4. [CNN, May 2026] Full cycle costs $25K-35K; current measures address only a fraction. 5. [congress_bills] All pro-IVF-coverage bills in 119th Congress remain in committee, no floor action. 6. [gdelt_news, June 2026] GOP-sponsored military IVF expansion killed during NDAA talks — signals even narrow GOP-backed IVF wins face internal resistance. # Cross-market signals - Kalshi related: No dedicated arbitrage market found; comparable "broken promise" markets (manufacturing 14.4%, gov't cuts 2%) trade similarly low, suggesting market-wide skepticism on Trump campaign-promise fulfillment markets. - Polymarket: No matching markets exist (0/100 scanned). - Sportsbook implied: N/A. # Analyst opinions and speculation - CNN (May 2026): experts say "much more needs to be done" — implies free IVF unlikely soon. - Code-execution Fermi model: base case ~8-10% (range 5-15%), driven by low odds of full zero-cost mandate vs. partial subsidies. - Democratic senators (Murray, Schumer) frame this as a "broken promise," implying no expectation of future free-IVF action from this administration. - Catholic bishops and pro-life groups pushing back even against modest coverage expansions — adds friction to any future action. # Directional lean per outcome - **Yes**: Some support from continued administration attention (EO, TrumpRx, proposed rules) showing IVF remains a live policy priority; possible narrow win (e.g., military/federal employee full coverage) could technically satisfy "at least one cycle" free. Still ~2.5 years remain until close. - **No** (favored): All concrete actions to date are partial/marginal; administration explicitly ruled out mandates; Congress gridlocked; GOP internal resistance (pro-life wing) constrains any broader move; cycle cost ($25-35K) far exceeds current relief (~drug cost only); Kalshi price stable at 15% despite steady news flow, indicating market sees no path forming. # Gaps / unknowns - Unclear whether any narrow population (e.g., military families, federal employees) could get a fully $0 cycle via a future rule — this is the most plausible path to Yes but no confirmed timeline exists. - Whether "eliminates the cost of at least one IVF cycle" could be satisfied by a state-federal hybrid or reconciliation-bill provision is untested/undefined by Kalshi rules. - No visibility into 2026-2028 legislative calendar/reconciliation vehicles that might attach an IVF provision. # Calibration anchors - Kalshi current YES price: **15%** (anchor, stable, thin volume). - Fermi/base-rate model: ~8-10% base case, 5-15% plausible range — somewhat below Kalshi's 15%, suggesting current price may be slightly rich for Yes, but structural uncertainty (2.5 yrs remaining, possible narrow-population action) keeps some optionality. - Precedent: administration's own EO produced no binding mandate 18 months later; similar "Trump promise" Kalshi markets (manufacturing, spending cuts) trade in the low-to-mid teens, reflecting a pattern of broken/incomplete campaign pledges.

1. Neither forecaster addresses the potential resolution ambiguity flagged in the brief's "Gaps/unknowns" section — the fact that "2 nationwide FEHB plans cover the full procedure" could already mean some federal employees get a $0 cycle today, which is arguably the single most concrete near-term path to YES and deserves explicit probability weight rather than being folded into a vague "narrow population action" caveat. 2. Both forecasts converge tightly (9% vs 11%) and essentially just restate the Fermi base case, showing herding rather than independent triangulation; neither explores why they should be *below* the thin-but-stable 15% Kalshi price rather than treating 15% as already reflecting informed traders' assessment of resolution-criteria ambiguity. 3. Neither considers election-cycle dynamics: with ~2.5 years remaining and 2028 being an election year, Trump/GOP may have strong incentive to deliver a symbolic "free IVF" action (e.g., a narrow but headline-grabbing military or Medicaid pilot) specifically to fulfill a signature campaign promise before leaving office — this tail scenario is underweighted. 4. The brief's point that "Republican-sponsored military IVF expansion was killed in NDAA talks" is used by both as purely bearish evidence, but neither notes this shows the issue remains actively contested and could resurface in a future NDAA cycle (multiple more NDAAs before 2029), which cuts against total dismissal of legislative paths. 5. Neither forecaster discusses potential 2027 reconciliation-bill vehicles (budget reconciliation only needs 51 Senate votes and bypasses filibuster) as a plausible path for an IVF-cost provision, despite the brief explicitly flagging "No visibility into 2026-2028 legislative calendar/reconciliation vehicles" as an unresolved gap. 6. Both treat the Kalshi thin-volume/no-repricing pattern as license to move below 15%, but an alternative reading is that professional traders already assign near-zero probability to news like TrumpRx or the excepted-benefits rule qualifying, and the 15% floor may instead reflect base-rate uncertainty about a full term's worth of surprise actions — arguing for anchoring closer to 15% rather than uniformly under it.

12% (medium confidence)

Yes: 12% No: 88%

All concrete actions through mid-2026 (non-binding EO, drug-only TrumpRx discounts, FEHB alignment, voluntary excepted-benefits rule with $120K cap) fall well short of eliminating a $25K–$35K cycle cost, the White House explicitly declined a coverage mandate, and Congress is stalled with even GOP-backed military IVF killed in NDAA talks. Both forecasters converged near the Fermi base case of 8–10%, but the critique is fair that they herded below a stable market price without weighing the genuine YES paths: possible resolution ambiguity around the 2 FEHB plans covering the full procedure, a symbolic pre-2028 election deliverable, future NDAA cycles, and a 2027 reconciliation vehicle. With ~2.5 years of optionality and undefined resolution criteria, shading far below the 15% Kalshi anchor is not well justified. I settle at 12% — modestly below the thin-market anchor to reflect the strongly negative substantive record, but above the Fermi base case to respect tail paths and resolution ambiguity.

Total pipeline time: 187.7s